Compare Heron Therapeutics Inc (HRTX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Impinj Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Impinj Inc trades at $136.43 (market cap $4.19B). The key difference: Impinj Inc is far larger — about 45.8× Heron Therapeutics Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | PI | |
|---|---|---|
Market Cap | $91.46M | $4.19B |
Sector | Health | Technology |
52-Week High | $1.96 | $241.91 |
52-Week Low | $0.39 | $91.34 |
Enterprise Value | $189.36M | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Impinj (PI) trades at $137.72, down 0.33% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported Q1 2026 EPS of $0.14, exceeding expectations, but maintains negative net income margins and high valuation multiples. Recent insider sales and mixed news flow highlight investor caution amid specialized RFID market positioning.
PI offers growth potential in RFID technology with strong analyst buy ratings (72.7% consensus) and a $167.50 price target, but faces significant risks from profitability challenges, high debt-to-asset ratio (51.52% in 2025), and competitive pressures. The stock's outlook hinges on execution improvement and market expansion to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
